According to our latest study, titled “Doxorubicin Market Forecast to 2028 – COVID-19 Impact and Global Analysis – By Drug Formulation, Distribution Channel, and Geography,” the market is expected to reach US$ 1,983.40 million in 2028 from US$ 1,390.64 million in 2022. It is estimated to grow at a CAGR of 6.1% during 2022–2028. The report highlights the key factors driving the global doxorubicin market growth and prominent players with their developments in the doxorubicin market.
Doxorubicin is a chemotherapy medication used to treat cancer. Liposomal doxorubicin is doxorubicin contained in tiny spheres called pegylated liposomes. These spheres keep the doxorubicin in the bloodstream longer, so that more of the drug reaches the cancer cells. Doxorubicin market application includes breast cancer, bladder cancer, Kaposi’s sarcoma, lymphoma, and acute lymphocytic leukemia and is given by injection into a vein.
Download PDF Sample Copy at:
The doxorubicin market is majorly comprised of top players involving Accord Healthcare; Cipla Inc.; Dr. Reddy’s Laboratories; Meiji Holdings Co., Ltd.; Janssen Pharmaceuticals (Johnson and Johnson Services, Inc.); Novartis AG; Pfizer Inc.; Sun Pharmaceutical Industries Ltd; Baxter International Inc.; Zydus Cadila, among others.
The companies listed above are implementing various strategies such as product launches, acquisitions, mergers, and partnerships, which have resulted in the company’s growth and, in turn, have brought about various changes in the worldwide market. Additionally, the companies have adopted several inorganic and organic strategies for accelerating their growth and improving their market position.
Below is the list of the growth strategies done by the players operating in the doxorubicin market:
Oct-21: Johnson & Johnson announced that it has acquired Momenta Pharmaceuticals, Inc. (Momenta), a company discovering and developing novel therapies for immune-mediated diseases, in an all-cash transaction for approximately 6.5 billion dollars completed. The acquisition expands Janssen’s leadership position in autoimmune diseases and represents an important catalyst for sustained growth
Aug-21: With the addition of next-generation, experimental immuno-therapeutics for hematological malignancies, the proposed purchase expands Pfizer’s category leadership in oncology. This increases the pipeline of fresh ideas, possibly improving growth in 2026–2030 and beyond
Have a Call with Analyst:
Aug-20: Johnson & Johnson announced that it has reached a definitive agreement to acquire Momenta Pharmaceuticals, Inc. (Momenta), a company discovering and developing novel therapies for immune-mediated diseases, in an all-cash transaction for approximately $6.5 This acquisition provides the Janssen Pharmaceutical Companies of Johnson & Johnson with an opportunity to extend their leadership in immune-mediated diseases and to drive further growth through expansion into autoantibody-mediated diseases. The transaction includes full global rights to nipocalimab (M281), a clinically validated, potentially best-in-class anti-FcRn antibody. Nipocalimab enables Janssen to reach significantly more patients by addressing indications in many autoimmune diseases with significant unmet medical needs in the areas.
Based on application, the global doxorubicin market is segmented into lung cancer, sarcoma, breast cancer, multiple myeloma, ovarian cancer, kidney cancer, leukemia, liver cancer, and others. In 2022, the breast cancer segment will likely hold the market’s largest share. Further, the kidney cancer segment is expected to witness growth in demand at the fastest CAGR from 2022 to 2028. The growing incidences of kidney cancer globally have led to the rise in the demand for doxorubicin. For instance, according to WHO, approximately 431,288 new cases of kidney cancer were registered, along with 179,368 deaths globally in 2020.
Based on drug formulation, the global doxorubicin market is segmented into lyophilized powder and doxorubicin injection. In 2022, the lyophilized powder will likely account for a larger share of the global market. Moreover, the same segment is anticipated to register the highest CAGR in the market from 2022 to 2028. The major driving factor for the growth of the lyophilized powder segment is its storage stability, which maintains its solid state at room temperature. Lyophilized powder can be used as a chemotherapy drug against various cancer types, such as lymphoma, carcinoma, and various sarcomas.
Buy Report at:
About The Insight Partners:
The Insight Partners is a one top industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Manufacturing and Construction, Technology, Chemicals and Materials.
We offer our clients multiple ways to customize research as per their specific needs and budget.
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi